Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
3
institutions
Market cap
$43.1B
165M shares
52-week range
$154.50 – $271.80
95% from low
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NYSE
CS
P/S (TTM)
2.6
EV / FCF (TTM)
22.6
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
www.iqvia.comNo one on the platform currently holds IQV.
| Institution | Shares | Reported |
|---|---|---|
| Appaloosa LPas of 2025-12-31 | 280,000 | $63.1M |
| Renaissance Technologiesas of 2025-06-30 | 103,047 | $16.2M |
No one on the platform has traded IQV yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 9.3% | 8.8% | 7.2% | — | — | — |
| Rev. Growth % | 5.9% | 7.5% | ||||
| Profit Margin % | 8.3% | 8.2% | 6.3% | |||
| Free Cash Flow Margin % | 12.6% | 12.8% | 10.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +4.9% on the P/E track.
At today's price, your expected annual return is +9.9% on the P/E track.
At today's price, your expected annual return is +14.6% on the P/E track.
| 47,119 |
| $8.0M |
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $17.4B | +7.6% | $12.97 | $12.92–$13.03 | 20.5× | 14 |
| 2027 | $18.4B | +5.8% | $14.42 | $13.99–$15.11 | 18.4× | 14 |
| 2028 | $19.5B | +5.9% | $16.15 | $14.03–$18.67 | 16.5× | 9 |
| 2029 | $20.8B | +6.7% | $18.31 | $18.12–$18.91 | 14.5× | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-28 | $3.03 | $3.15 | +4.0% |
| 2026-05-05 | $2.82 | $2.90 | +2.8% |
| 2026-02-05 | $3.40 | $3.42 | +0.6% |
| 2025-10-28 | $2.98 | $3.00 | +0.7% |
| 2025-07-22 | $2.77 | $2.81 | +1.4% |
| 2025-05-06 | $2.63 | $2.70 | +2.7% |
| 2025-02-06 | $3.11 | $3.12 | +0.3% |
| 2024-10-31 | $2.82 |
| $2.84 |
| +0.7% |
| $29.0B |
| — |
| HLNHaleon plc | $9.39 | +2.18% | $41.4B | — |
| HUMHumana Inc. | $407.45 | -0.57% | $48.9B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
IQVIA Holdings announced that its wholly owned subsidiary, IQVIA Inc., priced a $2 billion offering of senior notes due 2034. The notes will carry a 6.375% annual interest rate, with semiannual payments beginning March 15, 2027, and will mature on March 15, 2034. Proceeds will be used to fully redeem IQVIA’s existing 5.000% senior notes due 2026, repay part of the outstanding balance under its revolving credit facility, and cover fees and expenses related to the offering. The transaction is expected to close around Sept. 23, 2026, subject to customary closing conditions. The notes are being offered to qualified institutional buyers in the U.S. under Rule 144A and to non-U.S. investors outside the U.S. under Regulation S. IQVIA provides clinical research, commercial analytics and healthcare intelligence services to the life-sciences and healthcare industries, operating in more than 100 countries with approximately 94,000 employees. $IQV
View on StockTwits ↗
$IQV undiscovered breakout with 1229 watchers
View on StockTwits ↗
$IQV printed a new 52-week high today
View on StockTwits ↗$IQV printed a new 52-week high today
View on StockTwits ↗
$IQV is the AI Transformation partner of choice for Biotech/Big Pharma "19 of the largest 20 pharmaceutical companies are using IQVIA's AI technology in their operations" I like this company
View on StockTwits ↗$IQV printed a new 52-week high today
View on StockTwits ↗
$IQV printed a new 52-week high today
View on StockTwits ↗
$IQV Price: $259.82 (+1.47%) Trend: Bullish Market Bias (7D): Bearish Bias 📉 Expected Range: ±1.78% RSI: 71.8 | Momentum: Strong Momentum Volume: -26.5% vs avg Volatility: 3.67% Support: $206.87 | Resistance: $260.40 Data and analytics sourced from Thescanner educational research https://www.thescanner.ai
View on StockTwits ↗$IQV printed a new 52-week high today
View on StockTwits ↗
$MSCI $IQV $IBKR $WAT $HMC MSCI benefits from investment indexes and analytics demand, IQVIA benefits from pharmaceutical research and clinical-trial activity, Interactive Brokers benefits from trading and client-asset growth, Waters benefits from analytical and laboratory equipment demand, and Honda benefits from global vehicle demand. I'm watching asset flows, clinical spending, trading volumes, lab demand, and auto sales.
View on StockTwits ↗
$TEM $CAI $IQV $NTRA https://venturebeat.com/orchestration/stanford-is-running-37-000-ai-agents-as-a-virtual-biotech-and-one-of-its-drug-designs-got-independently-confirmed-by-merck
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.